Consumer Base and Services - As of September 30, 2024, NeueCare served approximately 404,000 consumers, including 347,000 value-based consumers and 57,000 fee-for-service consumers[198] - NeueSolutions had approximately 43,000 value-based care consumers attributed to its REACH ACOs and 119,000 enablement services lives as of September 30, 2024[199] - Year-over-year, value-based care consumers increased by approximately 35,000, driven by a rise of 55,000 through third-party payor relationships[208] - Enablement services lives grew to approximately 119,000, up from 31,000 in the previous year, indicating a substantial expansion in this segment[207] - NeueHealth aims to diversify and grow its consumer base across all product categories, including ACA Marketplace, Medicare, and Medicaid[202] Financial Performance - The company reported an Adjusted EBITDA of $9.396 million for the three months ended September 30, 2024, compared to $3.431 million for the same period in 2023, marking a significant increase[210] - As of September 30, 2024, the net loss was $40.365 million, a significant improvement from a net loss of $547.148 million for the same period in 2023[214] - Total revenue decreased by $36.5 million, or 13.5%, for the three months ended September 30, 2024, and $163.9 million, or 18.9%, for the nine months ended September 30, 2024, compared to the same periods in 2023[219] - ACO REACH revenue decreased by $50.6 million and $205.8 million for the three and nine months ended September 30, 2024, respectively, primarily due to a decrease of approximately 20,000 beneficiaries aligned to the REACH ACOs[219] - Capitated revenue increased by $11.0 million, or 18.2%, for the three months ended September 30, 2024, and $37.1 million, or 23.2%, for the nine months ended September 30, 2024, driven by increased membership through third-party payor contracts[230] Costs and Expenses - Medical costs decreased by $43.7 million, or 19.3%, for the three months ended September 30, 2024, and $174.5 million, or 23.8%, for the nine months ended September 30, 2024, primarily due to a decrease in beneficiaries aligned to the REACH ACOs[220] - Operating costs decreased by $8.5 million, or 11.7%, for the three months ended September 30, 2024, and $20.6 million, or 9.3%, for the nine months ended September 30, 2024, primarily due to a reduction in professional fees[221] - The operating cost ratio increased to 27.5% and 28.6% for the three and nine months ended September 30, 2024, respectively, reflecting a 60 and 310 basis points increase compared to the same periods in 2023[222] - Interest expense decreased by $4.6 million and $14.5 million for the three and nine months ended September 30, 2024, respectively, due to the payoff of the 2021 Credit Agreement in January 2024[225] - Loss from discontinued operations decreased by $53.5 million and $197.7 million for the three and nine months ended September 30, 2024, primarily due to the sale of the California Medicare Advantage business[229] Asset Management and Financing - The company recognized $11.4 million in impairments of intangible assets for the nine months ended September 30, 2024, related to classifying AMD as held-for-sale[223] - The company declared $28.2 million in dividends from regulated insurance entities during the nine months ended September 30, 2024, compared to no dividends in the same period of 2023[249] - As of September 30, 2024, the company was out of compliance with minimum risk-based capital and surplus levels for certain regulated insurance entities[250] - The company had $86.4 million in long-term borrowings under the Amended 2023 Credit Agreement as of September 30, 2024[260] - The Company has a term loan Tranche 2 of up to $25,000,000 available from November 10 to December 31, 2024, contingent on achieving specific funding milestones[263] Cash Flow and Investments - As of September 30, 2024, the Company had $226.4 million in cash and cash equivalents and $15.8 million in short-term investments[273] - The net cash used in operating activities for the nine months ended September 30, 2024, was $(98,823) thousand, a decrease of $2.3 billion compared to the same period in 2023[278] - Net cash provided by investing activities for the nine months ended September 30, 2024, was $189,230 thousand, a decrease of $956.2 million compared to the prior year[279] - The Company had net cash used in financing activities of $(239,274) thousand for the nine months ended September 30, 2024, an increase of $280.3 million compared to the same period in 2023[280] - As of September 30, 2024, the Company had letters of credit of $16.5 million and surety bonds of $19.7 million, with $33.7 million of cash and cash equivalents restricted as collateral[269] Shareholder Equity - The Centrum Promissory Note issued on October 29, 2024, has a principal of $64.0 million, due on October 29, 2028, with a cash interest rate of 6% per annum[270] - The Company issued 750,000 shares of Series A Preferred Stock for $750.0 million and 175,000 shares of Series B Preferred Stock for $175.0 million in previous financing rounds[271] - As of September 30, 2024, the Company had non-regulated cash and cash equivalents of $110.3 million, with $33.7 million restricted as collateral[274]

Financial Performance - NeueHealth reported revenue of $232.933 million for Q3 2024, a decrease of 13.5% compared to $269.399 million in Q3 2023[4] - Adjusted EBITDA for Q3 2024 was $9.396 million, up from $3.431 million in Q3 2023, marking the third consecutive quarter of positive Adjusted EBITDA[4] - Total revenue for the nine months ended September 30, 2024, was $704,019, down 19% from $867,931 in the same period of 2023[13] - ACO REACH revenue for the three months ended September 30, 2024, was $149,477, a decrease of 25.2% from $200,044 in the same period of 2023[17] - Total segment revenue for the nine months ended September 30, 2024, was $478,014, down 29.6% from $678,521 in the prior year[17] Consumer and Service Growth - The number of value-based consumers served increased to 390,000 in September 2024, up from 355,000 in September 2023, representing a growth of 9.86%[3] - Enablement services lives rose significantly to 119,000 in September 2024, compared to 31,000 in September 2023, indicating a growth of 283.87%[3] Revenue Projections and Guidance - For the full year 2024, NeueHealth expects revenue to be approximately $950 million, with NeueCare revenue projected at $320 million and NeueSolutions revenue at $640 million[5] - The company reaffirmed its Adjusted EBITDA guidance for 2024, expecting it to be between $15 million and $25 million[5] Assets and Liabilities - Total assets as of September 30, 2024, were reported at $696.783 million, a decrease from $1.225 billion as of December 31, 2023[12] - Total liabilities decreased to $1.009 billion as of September 30, 2024, down from $1.480 billion at the end of 2023[12] Cash Flow and Operating Activities - Cash and cash equivalents increased to $109.839 million in Q3 2024, compared to $87.299 million at the end of 2023[12] - Cash and cash equivalents at the end of the period were $226,413, down from $723,417 at the end of September 2023[15] - Net cash used in operating activities for the nine months ended September 30, 2024, was $(98,823), compared to $(2,395,319) in the same period of 2023[15] Operating Performance - Operating loss for Q3 2024 was $(17,342), a significant improvement compared to $(462,775) in Q3 2023[13] - Operating income for NeueCare in Q3 2024 was $16,430, compared to an operating loss of $(390,761) in Q3 2023[16] - Operating loss for the three months ended September 30, 2024, was $(5,832), an improvement from $(29,355) in the same period of 2023[17] Medical Costs - Medical costs for Q3 2024 were $182,693, a decrease of 19.3% from $226,438 in Q3 2023[13] - Medical costs for the three months ended September 30, 2024, were $153,840, a decrease from $204,017 in the same period of 2023[17] Cost Management - Total operating expenses for the nine months ended September 30, 2024, were $782,012, down from $1,398,992 in the same period of 2023[13] - Total operating expenses for the nine months ended September 30, 2024, were $486,381, down from $706,389 in the prior year[17] - The company plans to continue focusing on improving operational efficiency and reducing costs in future quarters[19] Losses - Net loss attributable to common shareholders for the nine months ended September 30, 2024, was $(170,383), compared to $(958,267) in the same period of 2023[13] - The company reported a net loss of $(40,365) for the three months ended September 30, 2024, compared to $(547,148) in the same period of 2023[21] Cost Ratios - The Operating Cost Ratio for the three months ended September 30, 2024, was 27.5%, up from 26.9% in the same period of 2023[22] - Adjusted Operating Cost Ratio for the three months ended September 30, 2024, was 18.2%, slightly down from 18.6% in the same period of 2023[22]

NeueHealth (NEUE) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Since a changing ear ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value NEUE New York Stock Exchange (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40537 NEUEHEALTH, INC. (Exact Name of Registrant as ...

| --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | NeueHealth Second Quarter 2024 - Earnings Presentation | | | | | | Privileged & Confidential \| © 2024 August 7, 2024 | | | | | Disclaimer Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward- ...

Financial Data and Key Metrics Changes - NeueHealth reported consolidated revenue of $226 million for Q2 2024, with a gross margin of $48.3 million and adjusted EBITDA of $4 million, indicating a moderate increase in consumers served compared to Q1 [13][19] - The company reaffirmed its expectation for full-year adjusted EBITDA to be between $15 million and $25 million [19] Business Line Data and Key Metrics Changes - In the NeueCare segment, revenue was $77 million, with operating income of $8.5 million before a long-lived asset impairment expense, which resulted in an operating loss of $5.9 million for the quarter [14] - The NeueSolutions segment generated revenue of $152.1 million, with an operating loss of $397,000, while serving approximately 113,000 consumers, exceeding expectations [15][11] Market Data and Key Metrics Changes - The company served over 477,000 consumers across the ACA Marketplace, Medicare, and Medicaid in Q2 2024, reflecting its ability to manage diverse populations [6][13] - For 2024, NeueHealth expects to serve between 475,000 and 500,000 consumers across both segments, with specific targets for value-based consumers [19] Company Strategy and Development Direction - NeueHealth is focused on a value-driven, consumer-centric care model that emphasizes long-term relationships with consumers and partnerships with providers [5][6] - The company is evaluating strategic growth opportunities and has a robust pipeline for 2025 and beyond, aiming to expand payer and provider partnerships [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's model and its ability to drive better health outcomes, highlighting the importance of consumer engagement and personalized care [5][21] - The company is well-positioned for sustainable growth in 2024 and beyond, supported by a new term loan facility of up to $150 million [4][18] Other Important Information - The wind-down of the ACA insurance business is progressing as planned, with approximately $135 million in excess cash at the end of Q2 2024 [16] - As of June 30, 2024, the company had $277.8 million in total cash and investments, strengthening its balance sheet [17] Summary of Q&A Session - The Q&A session concluded without any recorded questions or answers, indicating a focus on the presentation of results rather than interactive discussion [22]

Exhibit 99.1 NEUEHEALTH REPORTS SECOND QUARTER 2024 RESULTS | --- | --- | --- | |------------------------------------|-----------------------|------------| | Key Metrics | As of June \n2024 | 30, \n2023 | | Consumer and Patient Metrics | | | | Value-Based Consumers served | 364,000 | 373,000 | | Enablement Services Lives | 113,000 | 31,000 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------|-------|---------------------|----------------|------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40537 NEUEHEALTH, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4991296 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or oth ...

NeueHealth, Inc. (NYSE:NEUE) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Emily Lombardi - Investor Relations Mike Mikan - President and Chief Executive Officer Jay Matushak - Chief Financial Officer Conference Call Participants Marco Criscuolo - Nephron Research LLC Operator Good morning, everyone, and welcome to the NeueHealth Q1 2024 Earnings Call. My name is Drew, and I'll be the operator for today. After today's presentation, we will begin the Q&A session. [Operator Inst ...

Exhibit 99.1 NEUEHEALTH REPORTS FIRST QUARTER 2024 RESULTS DORAL, Fla. (May 8, 2024) (BUSINESSWIRE) – NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE: NEUE), the value- driven healthcare company, today reported financial results for its First Quarter ended March 31, 2024. "We had a strong start to the year, continuing to advance our value-driven, consumer-centric care model as we build on our strong relationships with providers and payors to make high-quality healthcare more accessible and affordable ...